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Clinical classification of early dementia and mild cogni-
tive impairment (MCI) is imprecise. We reported previ-
ously that molecular imaging classification of early
dementia and MCI with dual amyloid and dopamine
terminal positron emission tomography differs signifi-
cantly from expert clinical classification. We now
report pathological diagnoses in a substantial subset
of our previously imaged subjects. Among 36 subjects
coming to autopsy, imaging classifications and patho-
logical diagnosis were concordant in 33 cases
(j50.85). This approach enhanced specificity of Alz-
heimer’s disease diagnosis. The strong concordance of
imaging-based classifications and pathological diagno-
ses suggests that this imaging approach will be useful
in establishing more accurate and convenient classifica-
tion biomarkers for dementia research.
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Clinical classification of dementias, particularly inearly disease phases, is imprecise.1 There are three
common neurodegenerative dementias; Alzheimer disease
(AD), Lewy body dementia (LBD), and Frontotemporal
dementias (FTDs). Even expert clinical characterization
does relatively poorly in differentiating AD from FTDs.2
Clinical criteria for LBD possess good specificity, but rel-
atively poor sensitivity.3 Mild cognitive impairment
(MCI), a common precursor of dementia, is a heteroge-
neous category associated with all major neurodegenera-
tive pathologies and vascular etiologies. Imprecise classifi-
cation of MCI and early dementia subjects is an obstacle
to clinical research owing to the fact that heterogeneous
study populations dilute power to detect effects of trial
interventions or associations with potential biomarkers.
The emergence of positron emission tomography (PET)
ligands identifying specific pathological features of neuro-
degenerative disorders raises the possibility of minimally
invasive characterization of MCI and early dementia sub-
jects. We previously reported results of combined amy-
loid ([11C]PIB) and dopamine terminal ([11C]DTBZ)
PET imaging in 102 MCI and early dementia subjects,
demonstrating only moderate concordance (j5 0.41)
between imaging-based and expert clinical consensus clas-
sifications.4,5 Our previous results raise the possibility
that this imaging-based approach to classification more
faithfully reflects underlying pathologies than clinical
characterization. We now report neuropathological
follow-up of a substantial fraction of our study subjects.
Subjects and Methods
Study participants were individuals with MCI or relatively mild
dementia (Mini–Mental State Examination [MMSE]> 17) as
described previously and enrolled in our previous imaging study
from 2005 to 2009.4,5 The purpose of the previous study was
to compare amyloid-dopamine terminal PET-based classifica-
tion of early cognitive impairment subjects with expert clinical
classification. Subjects with primary features of cognitive
impairment were recruited from the University of Michigan
Cognitive Disorders Clinic. Patients with primary neurological
presentations involving noncognitive domains (ataxia, parkin-
sonism, and so on) were excluded. Inclusion-exclusion criteria
are described in previous publications; patients with possible
vascular dementia (modified Hachinski score> 4 or meeting
NINDS-AIREN criteria or large infarcts on structural imaging)
were excluded.4 Clinical classifications were established by
expert consensus conference based on clinical and
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neuropsychological data accumulated at the time of visits for
imaging, as described previously.4 Enrollees agreed to follow-up
autopsy. To date, 41 study participants died and autopsies were
completed on 36. Autopsy results of 1 subject were reported
previously.6 All autopsies were performed at the University of
Michigan Health System. Neuropathology was assessed by
standard methods and using standard diagnostic criteria.7–11
The examining neuropathologists (A.F.-H., A.P.L., and S.C.-P.)
were blind to results of imaging studies. Thal scores of amyloid
plaque density were compiled for three neocortical regions;
mid-frontal (Brodmann’s areas [BA] 10 and 46), parietal (BA 7
and 39), and primary occipital (BA 17). Plaques were identified
with Ab immunohistochemistry (6F/3D; 1:50; Leica Biosys-
tems, Nussloch, Germany). Thal scoring was available for all
subjects. Regional [11C]PiB binding was quantified as distribu-
tion volume ratios (DVRs) with the cerebellar gray matter as
the reference region. Image-based classifications established in
our previous studies were used for categorical comparison with
pathological diagnoses.4,5 Standardized DVR image data sets
were classified qualitatively by an expert interpreter (K.A.F.)
familiar with the normal and pathological distributions of these
tracers and blind to all clinical and routine structural imaging
data, as described previously.4 In our previous study, use of
parametric regional DVR thresholds for classification did not
alter results.4 The unweighted Cohen’s kappa statistic was used
to estimate concordance between imaging based and pathologi-
cal classifications. Spearman’s rank-order correlation was used to
compare amyloid burden assessed pathologically with the
[11C]PiB DVR estimates of regional amyloid burden. Sixteen
subjects also underwent [18F]fluorodeoxyglucose PET (FDG-
PET) at the same time they underwent DTBZ-PiB imaging.
These studies were interpreted by the same expert interpreter
(K.A.F.) blind to the clinical histories, and structural and PET
imaging data.
Results
There was overall excellent concordance of imaging based
classifications with neuropathological diagnoses
(j5 0.85; 95% confidence interval5 0.69–1.0; Table 1;
details of pathological results in Supplementary Table).
Regional amyloid DVRs correlated well with neuropatho-
logical scoring of amyloid burden in the selected neocort-
ical regions (Fig). For mid-frontal cortex, rho5 0.72; for
parietal cortex, rho5 0.79; for primary occipital cortex,
rho5 0.64 (all p< 0.05). There were 3 cases with dis-
cordant imaging-pathological classifications. One subject
had a clinical diagnosis and imaging classification of
LBD, but a pathological diagnosis of AD. Alpha-
synuclein immunoreactive Lewy bodies were found in
midbrain neurons in this subject, suggesting the presence
of mixed AD-LBD pathology. The second discordant
subject had marked frontal and temporal atrophy second-
ary to multiple small infarctions and imaging classifica-
tion as FTD. The final discordant case was classified by
imaging as LBD, but remarkable only for the presence of
transactive response DNA binding protein 43 kDa
(TDP-43)-immunoreactive neurites in the frontal cortex
and hippocampal formation. This was an unusual case in
that there was marked unilateral striatal loss of
[11C]DTBZ binding. Three cases were assessed patholog-
ically as meeting criteria for both AD and LBD. These
individuals had imaging classifications as LBD with amy-
loid deposition and are assessed as concordant classifica-
tions. There was excellent concordance between imaging
assessments of increased amyloid burden and pathological
results; all subjects found to have moderate-to-high amy-
loid plaque burden at autopsy were classified as amyloid
positive in imaging classifications.
We performed a more limited comparison of com-
bined amyloid and dopamine terminal imaging classifica-
tions, neuropathological diagnoses, and FDG-PET
classifications. Approximately 30% of the FDG-PET
classifications differed from final neuropathological diag-
noses (Table 2). There were 3 cases where the FDG-PET
classification was FTD with pathological diagnoses of
AD and 2 cases where the FDG-PET classification was
AD with pathological diagnoses of LDB. In all cases
with discrepant FDG-PET classifications and neuropath-
ological diagnoses, combined amyloid and dopamine ter-
minal PET imaging correctly identified the pathological
diagnosis (Table 2).
FIGURE 1: Scatter plot of parietal cortex Thal scores
(autopsy rating) versus [11C]PiB DVRs. PET5positron emis-
sion tomography; DVR5distribution volume ratio;
[11C]PiB5Pittsburgh B; r5Spearman’s rho.
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Discussion
Our results indicate that classifications based on com-
bined amyloid and dopamine terminal PET imaging cor-
relate well with neuropathological diagnostic classifica-
tions. Of 36 subjects studied, there were 3 cases (8.3%)
where imaging based and pathological classifications dif-
fered. In our previous studies, in contrast, 35% of par-
ticipants had discordant expert clinical consensus and
imaging diagnostic classifications.4,5 One discordant case
was classified as LBD on the basis of significantly
reduced striatal [11C]DTBZ binding. Though not meet-
ing pathological criteria for LBD, this subject had nigral
Lewy bodies, suggesting mixed pathology.
Our results are consistent with other recent studies.
In trials of antiamyloid therapy of clinically classified
early AD subjects where participants underwent amyloid
imaging, 15% of enrolled subjects had negative amy-
loid imaging, excluding AD.12–14 These results likely
underestimate diagnostic misclassifications given that
50% of LBD cases exhibit significant amyloid burden,
likely leading to misclassification of some LBD subjects
as AD.15 A clinicopathological study using the National
Alzheimer’s Coordinating Center (NACC) data set found
that 15% of classified clinically AD subjects failed
pathological criteria for AD.16 In our previous studies, a
major cause of discrepant clinical and imaging classifica-
tions were subjects classified clinically as FTD, but with
positive amyloid imaging results suggesting AD.4 Our
results comparing amyloid/dopamine terminal imaging
and clinical diagnostic classifications are similar to those
reported by Beach et al. using the NACC data set to
compare clinical and neuropathological diagnoses.17
Our limited evaluation of FDG-PET classifications
suggests that this method is less precise than combined
amyloid and dopamine terminal PET imaging. These
types of FDG-PET misclassifications are well described
in previous literature. Disproportionate frontal amyloid
deposition may give rise to frontal predominant hypome-
tabolism.18 The canonical pattern of cerebral metabolic
deficits in LDB is the pattern of temporoparietal and
frontal deficits found in AD plus occipital hypometabo-
lism, but the distinguishing occipital metabolic deficits
are absent is a significant fraction of patients.19
Amyloid imaging is accepted as a useful biomarker
of fibrillar amyloid deposition. The high prevalence of
amyloidopathy in LBD, however, indicates that increased
amyloid burden is not a unique AD biomarker. Combin-
ing amyloid imaging with a dopamine terminal marker
enhances accuracy. Our study, and this approach in gen-
eral, has some limitations. Our number of autopsied sub-
jects is relatively small. Because amyloid imaging is rela-
tively sensitive for detecting AD, and dopamine terminal
imaging allows exclusion of LBD, this method is argu-
ably best at improving identification of AD. Two of the
imaging misclassifications assessed subjects as LBD were
found at autopsy to have another diagnosis. This result
and the existence of nigrostriatal pathology in FTD and
related syndromes indicate that dopamine terminal imag-
ing possesses good sensitivity, but less specificity, for
detection of LBD. In amyloid-negative individuals, sub-
stantial nigrostriatal terminal loss could indicate either
LBD or FTD, given that some FTD patients develop
parkinsonism with nigrostriatal degeneration, particularly
those with MAPT or GRN mutations, decreasing the
specificity of this approach of accurate classification of
LBD.20 Identification of FTD is most problematic given
that our classification of FTD is based on negative imag-
ing results—the absence of pathological amyloid or dopa-
mine terminal imaging changes. This may be misleading
because there are multiple potential causes of cognitive
impairment without amyloid or nigrostriatal pathology,
for example, our case where the neuropathological evalu-
ation revealed multiple small infarcts instead of neurode-
generation. Positive imaging markers for tau deposition
and other FTD-associated pathologies would be useful
additions to this imaging approach.21
Our results point to another problem secondary to
use of the trinary classification scheme. This conventional
approach is artificial in that mixed pathologies are com-
mon, though the presence of other pathologies does not
confound amyloid ligand binding.22 Mixed pathologies
are observed in our data set with 3 subjects with both
AD and LBD, and the discordant subject who met neu-
ropathological criteria for AD and had midbrain Lewy
bodies. Identification of individuals with both AD and
LBD is particularly difficult, both with our dual tracer
approach and with conventional clinical classifications.
This is an area where addition of a tau tracer may be
valuable.
Our study has significant advantages. Our subjects
were enrolled during relatively early disease stages, either
MCI status or relatively mild dementia (MMSE> 17).
Previous studies correlating amyloid imaging results with
neuropathology enrolled individuals with advanced
dementia.23–26 Our study population is more typical of
clinical research studies and offers reassurance that previ-
ous imaging-pathological correlation studies of amyloid
imaging are relevant to earlier phases of neurodegenera-
tion. Our study design may underestimate the utility of
this multitracer approach. Imaging classifications were
made in the absence of clinical and structural (computed
tomography or magnetic resonance imaging) imaging
information. Conversely, our clinical classifications were
ANNALS of Neurology
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made without the PET results. Use of this multitracer
PET approach in conjunction with clinical and structural
imaging data would likely enhance accuracy of classifica-
tions. These methods may provide additional useful data.
We showed previously that regional cerebral blood flow
data derived from [11C]DTBZ PET closely mimics the
patterns of regional cerebral metabolism visualized with
[18F]FDG-PET imaging.27,28 Analysis of [11C]DTBZ-
based regional perfusion data would add a functional
dimension to analysis and might further enhance classifica-
tions. Individuals, for example, with abnormal striatal
[11C]DTBZ ligand binding could have either LBD or
FTD. These syndromes exhibit distinctive regional cerebral
metabolic-perfusion deficit patterns, which could be help-
ful in classifying LBD and FTD subjects more accurately.
We do not suggest that this approach to classifica-
tion would be broadly useful in clinical practice. It is
more plausible that this approach, or approaches using
similar tracers or incorporating additional tracers, such as
a tau ligand, will be useful in clinical research. These
methods may allow purer subject samples or better sub-
ject stratification, particularly for selection of AD sub-
jects, for clinical research studies. This approach may be
useful in establishing the utility of more accessible classi-
fication biomarkers. Rather than waiting years for
autopsy results, this dual tracer approach or similar
methods could be used as surrogates to validate more
convenient classification biomarkers.
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TABLE 2. Expert consensus clinical classifications, PiB-DTBZ imaging classifications, neuropathological
diagnoses, and FDG-PET classifications
Clinical
Consensus
Classification
Age at
Initial
Evaluation
Age at
Imaging
Classification
Age at
Death
Disease
Duration
PiB-DTBZ
Imaging
Classification
Pathologic
Diagnosis
FDG-PET
Classification
AD 59 60 66 7 AD AD AD
LBD 68 70 71 3 LBD LBD AD
AD 64 65 67 3 AD AD FTD
AD 69 71 73 4 AD AD AD
LBD 75 79 86 11 LBD LBD LBD
LBD 74 74 79 5 LBD LBD LBD
LBD 65 66 73 8 LBD LBD AD/LBD
mdMCI 65 65 66 1 AD AD AD
aMCI 77 80 83 5 AD AD FTD
AD 76 81 82 6 AD AD AD
AD 85 85 89 4 AD AD FTD
AD 66 67 72 6 LBD LBD AD
aMCI 79 80 84 5 AD AD AD
AD 65 68 72 7 LBD LBD1AD LBD
LBD 76 77 83 7 AD AD AD
AD 56 59 63 7 AD AD AD
Disease duration5 interval from age at initial evaluation to age at death.
AD5Alzheimer’s disease; LBD5 Lewy body dementia; FTD5 frontotemporal dementia; MCI5mild cognitive impairment;
aMCI5 amnestic MCI; mdMCI5multidomain MCI; PiB-DTBZ5 [11C]Pittsburgh B and [11C]dihydrotetrabenazine positron
emission tomography; FDG-PET5 [18F]fluorodeoxyglucose/positron emission tomography. FDG-PET classification criteria: AD:
temporoparietal and posterior cingulate hypometabolism; LDB: temporoparietal and posterior cingulate hypometabolism plus occi-
pital hypometabolism; FTD: frontal, anterior temporal, and anterior cingulate hypometabolism.
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